Abstract: A collar of a fixed scroll includes a gasket contact surface with which a gasket comes into contact, and a metal contact surface that causes the collar and a compression housing to be in contact and receives the axial force of bolts. The collar has a protruding portion that protrudes in the axial direction relative to the gasket contact surface, and the metal contact surface is disposed on the protruding portion.

Abstract: A collar of a fixed scroll includes a gasket contact surface with which a gasket comes into contact, and a metal contact surface that causes the collar and a compression housing to be in contact and receives the axial force of bolts. The collar has a protruding portion that protrudes in the axial direction relative to the gasket contact surface, and the metal contact surface is disposed on the protruding portion.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: A method of effecting feedback control of the air-fuel ratio of an air-fuel mixture being supplied to an internal combustion engine, to bring the air-fuel ratio to desired values by correcting a fuel quantity to be supplied to the engine by means of a correction coefficient which varies in response to output from an exhaust gas concentration sensor, when the engine is operating in an air-fuel ratio feedback control region. An average value of values of the correction coefficient obtained is calculated while the engine is operating in the feedback control region. The calculated average value is corrected in dependence on a temperature of the engine and the feedback control is initiated by using the corrected average value as an initial value of the correction coefficient when the engine has shifted into the feedback control region from the another region. The calculated average value is corrected to such a value as to make the air-fuel ratio leaner as the engine temperature is lower.

Abstract: Air intake side secondary air supply system for an internal combustion engine includes first and second secondary air supply passages leading to an intake manifold in which an open/close valve and an air control valve are respectively provided for a proportional control and an integral control of secondary air. In order to improve a driveability of the engine during a transition period from a feedback control mode to an open loop control mode, pressure control device for controlling a supply of first and second control pressures respectively for opening and closing the air control valve is constructed to rapidly supply the second control pressure when a state of engine operation in which the feedback control mode is to be stopped is detected.